SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is trending as disappointing delivery figures, including a recent January decline, and multiple analyst downgrades fuel community debate, with some viewing it as an oversold opportunity while others cite intense competition and a weakening sales outlook in the crowded EV market.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as geopolitical tensions elevate defense sector interest, alongside recent news of increasing aircraft deliveries and substantial new orders. The community is debating a potential defense-driven surge against the company's persistent production challenges and struggles to translate positive commercial developments into consistent stock performance.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending amid concerns that AI agents and stablecoins could disrupt its traditional interchange fee model, triggering a sector-wide sell-off. However, many investors see this as an overreaction, highlighting the company's strong earnings, share buybacks, and strategic adaptation to new payment technologies.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy (EOSE) is experiencing high volatility after its latest earnings report missed revenue and earnings expectations alongside weak guidance, triggering a sharp decline in share price. While some investors express significant concern over management's execution and credibility, others view the steep sell-off as an overreaction, pointing to strong revenue growth, a substantial backlog, and the long-term demand for its energy storage technology.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE is trending due to its strong, cult-like community relentlessly building around its narrative as the "third frog" and official representation of Pepe by creator Matt Furie. Despite market conditions, the community views it as a resilient and undervalued asset on Ethereum, widely discussed as the next major frog memecoin.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United Airlines (UAL) is a hot topic following mixed Q3 earnings that revealed an EPS beat but a revenue miss, despite optimistic Q4 guidance, with investors' apprehension heightened by the escalating U.S. government shutdown and significant put options activity signaling bearish sentiment.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is experiencing intense debate as its leveraged Ethereum treasury status ties it directly to highly volatile crypto prices, with community discussion polarized between bullish hopes for a recovery fueled by ETH accumulation and bearish warnings of further downside amidst geopolitical concerns and alleged market manipulation.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending due to upcoming earnings and its strategic acquisition of Shackleton Finance, with the community actively debating if these catalysts will finally overcome persistent short interest by enabling large-scale project financing and correcting its perceived undervaluation.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as escalating geopolitical conflicts in the Middle East drive community discussion around the increasing role of drones in modern warfare and the potential for a significant boost to defense stocks. This comes as analysts highlight Ondas as a preferred pick in the rapidly expanding drone market, fueling speculation about its technology's critical deployment and its connection to Israeli defense systems.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending ahead of its Q4 earnings report and upcoming presentations at the AAAAI meeting, where new data on its long-acting navenibart and ORLADEYO are eagerly anticipated. The community is actively discussing the stock's potential for a short squeeze, fueled by high short interest and perceived undervaluation relative to its pipeline and expected profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos to Participate in Upcoming Investor Conferences

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle...

<ul class="summary-bullets"><li>MSLE stock&nbsp;was down about 2%&nbsp;in overnight trading heading into Tuesday.</li><li>The company completed a $57.2 million public offering to fund its lead drug, SAT-3247, and other research into muscle diseases.</li><li>Early data for SAT-3247 is expected in the second quarter of 2026, following encouraging adult safety results.</li></ul>Shares of Satellos Bioscience Inc. (MSLE) opened more than 10% above their offering price in the company’s Nasdaq debut on Monday before ending the session more than 3% lower and dipping over 8% in after-hours trading.Investor sentiment took a hit after the company revealed it had completed an equity raise to fund its Duchenne muscular dystrophy (DMD) program and broader muscle disease research.&nbsp;<h2 class="st-heading-2">MSLE Wraps Up Equity Raise</h2>Satellos said it has completed its underwritten public offering, raising about $57.2 million before fees. The deal included roughly 5.2 million common shares, along with pre-funded warrants for some investors. The <a href="https://stocktwits.com/symbol/MSLE">shares of Satellos</a> were sold at $10.1 each. The stock is also listed on the Toronto Stock Exchange under the MSCL ticker.The company said the funds will mainly support research and development, with a focus on advancing SAT-3247, its lead drug candidate, into mid and late-stage clinical trials. Some of the money will also be used to explore additional muscle-related diseases and support early-stage research programs.Ahead of the Nasdaq listing, Satellos carried out a 1-for-12 share consolidation in late January. This reduced the total number of shares from about 185.5 million to roughly 15.5 million, helping the stock meet Nasdaq’s listing requirements.<h2 class="st-heading-2">How SAT-3247 Works</h2>SAT-3247 is an oral drug designed to help the body repair and regenerate muscle by targeting a protein called AAK1, which plays a role in muscle stem cell signaling. Unlike gene therapies, SAT-3247 does not depend on fixing the dystrophin gene, meaning it could potentially work for a wide range of Duchenne patients, regardless of their specific genetic mutation.In December, Satellos received FDA clearance and approvals from global regulators to begin a Phase 2 clinical study of SAT-3247 in 51 children with Duchenne. The study will test safety and measure changes in muscle strength and function. The company expects early trial results in the second quarter of 2026. Earlier studies in adults showed that the drug was well tolerated and associated with improvements in grip strength over a 28-day treatment period.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Satellos Bioscience was ‘neutral’ amid ‘extremely low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/msle_ss_png_8d0bdc8b59.webp" alt="msle ss.png" width="973" height="142"><figcaption>MSLE sentiment and message volume as of February 10 | Source: Stocktwits</figcaption></figure>One user said the company’s “Clinical results should be pretty stellar.”<stembedurl>https://stocktwits.com/bruceleeboy/message/644522213</stembedurl>Another user said, “It looks like all went well with the listing. Great work. Let’s see if we&nbsp; get something going this Spring.”<stembedurl>https://stocktwits.com/PennyScam/message/644421647</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Satellos Bioscience Inc. (MSLE) opened more than 10% above their offering price in the company’s Nasdaq debut on Monday. (Photo credit: Getty Images)

Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours

SAT-3247, an oral therapy aimed at restoring muscle repair, is now in Phase 2 testing in children with DMD.

Equity

Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters Option to Purchase Additional Shares

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

MSLE
Satellos Bioscience Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest MSLE News

MSLESatellos Bioscience Inc